Craft
  • Home
  •  / Novo Nordisk
Novo Nordisk

Novo Nordisk

Phase I Trials Products (Haemophilia)

1

Q4, 2020

Revenue

KR140.8 B

FY, 2021

Market Capitalization

KR1.7 T

2022-09-19

Novo Nordisk Summary

Company summary

Overview
Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products. It operates through two segments: Diabetes and Obesity care and Biopharm. The Diabetes and Obesity care segment covers insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment covers the therapy areas of haemophilia, growth disorders, and hormone replacement therapy.
Type
Public
Founded
1923
HQ
Bagsværd, DK | view all locations
Website
https://www.novonordisk.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Lars Fruergaard Jørgensen

    Lars Fruergaard Jørgensen, President and Chief Executive Officer

  • Monique Carter

    Monique Carter, Executive Vice President and Head of People & Organisation

  • Maziar Mike Doustdar

    Maziar Mike Doustdar, Executive Vice President and Head of International Operations

  • Ludovic Helfgott

    Ludovic Helfgott, Executive Vice President and Head of Rare Disease

Operating MetricsView all

Phase I Trials Products (Diabetes)

7
250.0%

Q4, 2020

Phase III Trials Products (Diabetes)

6
500.0%

Q4, 2020

Trials Products Approved (Obesity)

1

Q4, 2020

LocationsView all

109 locations detected

  • Bagsværd HQ

    Denmark

    Novo Allé 1

  • Cambridge, MA

    United States

    255 Main St #10th

  • Clayton, NC

    United States

    3612 Powhatan Rd

  • Durham, NC

    United States

    5235 International Dr

  • Fremont, CA

    United States

    6300 Dumbarton Cir

  • Indianapolis, IN

    United States

    5225 Exploration Dr

and 103 others

Novo Nordisk Financials

Summary financials

Revenue (Q2, 2022)
kr41.3B
Gross profit (Q2, 2022)
kr37.0B
Net income (Q2, 2022)
kr13.3B
Cash (Q2, 2022)
kr22.8B
EBIT (Q2, 2022)
kr18.4B
Enterprise value
$1.7T

Footer menu